Claris Lifesciences announced its annual audited financial results for the year ended December 31, 2013 at its recently held board meeting in Ahmedabad. The consolidated revenues for the full year; after transfer of the infusion business to the JV during the third quarter; stood at Rs 7,084 million and for the Q4CY13 stood at Rs 1,675 million compared to Rs 7,777 million and Rs 1,947 million; respectively; in the same period for the previous year.
The revenues for the quarter and year have dropped due to the transfer of the Infusion business in India and emerging markets to the Joint Venture.
Consolidated earnings before interest, depreciation, taxes and amortization (EBITDA) stood at Rs 2,100 million for CY13 and Rs 377 million for the Q4CY13. EBITDA margins were at 32 per cent to net sales for the year ended on December 31, 2013.
Consolidated profit after tax (PAT) for CY13 and Q4CY13 stood at Rs 844 million and Rs 178 million respectively, compared to Rs 1039 million and Rs 252 million for the same period in the previous year. The PAT margins were at 13 per cent of the net sales for year ended on December 31, 2013.
The PAT for the quarter and year have dropped as compared to the previous year due to the transfer of the Infusion business in India and emerging markets to the joint venture.
EP News Bureau – Mumbai